143 related articles for article (PubMed ID: 1728313)
21. A rapid assay for evaluation of iron-chelating agents in rats.
Pippard MJ; Johnson DK; Finch CA
Blood; 1981 Oct; 58(4):685-92. PubMed ID: 7272500
[TBL] [Abstract][Full Text] [Related]
22. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
Morel I; Cillard J; Lescoat G; Sergent O; Pasdeloup N; Ocaktan AZ; Abdallah MA; Brissot P; Cillard P
Free Radic Biol Med; 1992 Nov; 13(5):499-508. PubMed ID: 1334028
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
Chenoufi N; Hubert N; Loréal O; Morel I; Pasdeloup N; Cillard J; Brissot P; Lescoat G
J Hepatol; 1995 Aug; 23(2):166-73. PubMed ID: 7499788
[TBL] [Abstract][Full Text] [Related]
24. Chelation of aluminium by combining DFO and L1 in rats.
Blanusa M; Prester L; Varnai VM; Pavlović D; Kostial K; Jones MM; Singh PK
Toxicology; 2000 Jul; 147(3):151-6. PubMed ID: 10924797
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization.
Hershko C; Grady RW; Cerami A
J Lab Clin Med; 1978 Aug; 92(2):144-51. PubMed ID: 681807
[TBL] [Abstract][Full Text] [Related]
26. Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function.
Pattanapanyasat K; Webster HK; Tongtawe P; Kongcharoen P; Hider RC
Br J Haematol; 1992 Sep; 82(1):13-9. PubMed ID: 1419787
[TBL] [Abstract][Full Text] [Related]
27. Storage iron exchange in the rat as affected by deferoxamine.
Kim BK; Huebers H; Pippard MJ; Finch CA
J Lab Clin Med; 1985 Apr; 105(4):440-8. PubMed ID: 3920336
[TBL] [Abstract][Full Text] [Related]
28. Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats.
Zanninelli G; Choudury R; Loréal O; Guyader D; Lescoat G; Arnaud J; Verna R; Cosson B; Singh S; Hider RC; Brissot P
J Hepatol; 1997 Jul; 27(1):176-84. PubMed ID: 9252093
[TBL] [Abstract][Full Text] [Related]
29. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
[TBL] [Abstract][Full Text] [Related]
30. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
Lau EH; Cerny EA; Wright BJ; Rahman YE
J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
[TBL] [Abstract][Full Text] [Related]
31. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
Florence A; Ward RJ; Peters TJ; Crichton RR
Biochem Pharmacol; 1992 Sep; 44(6):1023-7. PubMed ID: 1417929
[TBL] [Abstract][Full Text] [Related]
32. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
Vlachodimitropoulou Koumoutsea E; Garbowski M; Porter J
Br J Haematol; 2015 Sep; 170(6):874-83. PubMed ID: 26033030
[TBL] [Abstract][Full Text] [Related]
33. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
Chua AC; Ingram HA; Raymond KN; Baker E
Eur J Biochem; 2003 Apr; 270(8):1689-98. PubMed ID: 12694182
[TBL] [Abstract][Full Text] [Related]
34. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and evaluation of N-basic substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotrophic potential.
Liu ZD; Khodr HH; Lu SL; Hider RC
J Pharm Pharmacol; 2000 Mar; 52(3):263-72. PubMed ID: 10757413
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
Rai BL; Dekhordi LS; Khodr H; Jin Y; Liu Z; Hider RC
J Med Chem; 1998 Aug; 41(18):3347-59. PubMed ID: 9719587
[TBL] [Abstract][Full Text] [Related]
37. Effect of iron chelation on the in-vitro growth of Leishmania promastigotes.
Soteriadou K; Papavassiliou P; Voyiatzaki C; Boelaert J
J Antimicrob Chemother; 1995 Jan; 35(1):23-9. PubMed ID: 7768775
[TBL] [Abstract][Full Text] [Related]
38. Long-term trials of deferiprone in Cooley's anemia.
Olivieri NF; Brittenham GM
Ann N Y Acad Sci; 1998 Jun; 850():217-22. PubMed ID: 9668542
[TBL] [Abstract][Full Text] [Related]
39. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.
Porter JB; Morgan J; Hoyes KP; Burke LC; Huehns ER; Hider RC
Blood; 1990 Dec; 76(11):2389-96. PubMed ID: 2257308
[TBL] [Abstract][Full Text] [Related]
40. The antimalarial effect of iron chelators: studies in animal models and in humans with mild falciparum malaria.
Hershko C; Gordeuk VR; Thuma PE; Theanacho EN; Spira DT; Hider RC; Peto TE; Brittenham GM
J Inorg Biochem; 1992 Aug 15-Sep; 47(3-4):267-77. PubMed ID: 1431886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
